Sarepta Therapeutics (SRPT) Rating Increased to Strong-Buy at BidaskClub
BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a strong-buy rating in a report published on Friday.
A number of other research firms have also commented on SRPT. JPMorgan Chase upped their price target on Sarepta Therapeutics from $75.00 to $95.00 and gave the company an overweight rating in a research report on Wednesday, March 14th. Royal Bank of Canada reaffirmed a buy rating and set a $91.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, March 14th. SunTrust Banks increased their target price on Sarepta Therapeutics to $95.00 and gave the stock a buy rating in a research report on Friday, March 16th. Morgan Stanley lowered Sarepta Therapeutics from an overweight rating to an equal weight rating and increased their target price for the stock from $64.00 to $87.00 in a research report on Wednesday, March 21st. Finally, Credit Suisse Group reissued a hold rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research report on Monday, March 12th. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Sarepta Therapeutics has a consensus rating of Buy and a consensus price target of $78.87.
SRPT opened at $78.46 on Friday. The company has a market cap of $5,250.25, a price-to-earnings ratio of -47.84 and a beta of 1.28. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. Sarepta Therapeutics has a one year low of $28.82 and a one year high of $84.37.
A number of hedge funds have recently bought and sold shares of SRPT. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sarepta Therapeutics by 39.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares in the last quarter. Prentiss Smith & Co. Inc. bought a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $199,000. Arrowstreet Capital Limited Partnership bought a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $217,000. Finally, Aperio Group LLC bought a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $219,000. 84.98% of the stock is owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.